Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
3 minute read

MorphoSys Presented New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022

By Charles Gross
December 11, 9:09 PM
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced results from analyses of the ongoing MANIFEST study, an open-label Phase 2 clinical trial of pelabresib, an investigational BET inhibitor, in patients with myelofibrosis, a type of bone marrow cancer with limited treatment options.

MOR

Read More
1 minute read

MorphoSys Shares Higher Premarket After Co Announced on Tuesday an Upfront Payment of $23M from Novartis for Exclusive Worldwide Rights for Pre-clinical Inhibitors of a Novel Cancer Target

By Charles Gross
December 7, 5:52 AM
MorphoSys announced on Tuesday, that its fully owned subsidiary Constellation Pharmaceuticals, Inc. has entered into a global licensing agreement with Novartis to research, develop and commercialize its pre-clinical inhibitors of a novel cancer target. This program was added to MorphoSys' research portfolio following its acquisition of Constellation Pharmaceuticals, Inc.

MOR